PTC Stock Recent News
PTC LATEST HEADLINES
Collaboration to Drive PTC's Onshape Initiatives Including Discovery Program, Onshape AI Advisor, and CAD and PDM Conversion Tools BOSTON , Sept. 25, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced entry into a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to accelerate the growth of its Onshape® cloud-native computer-aided design (CAD) and product data management (PDM) solution.
BOSTON , Sept. 3, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Rob Bernshteyn to its Board of Directors, effective September 9, 2024.
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
WARREN, N.J. , Aug. 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Thursday, Sept.
BOSTON , Aug. 27, 2024 /PRNewswire/ -- PTC (Nasdaq: PTC) today announced that it will participate in the following conferences. What: Citi's 2024 Global TMT Conference When: Wednesday, September 4th, 2024 at 8:20am ET What: 2024 RBCCM Global TIMT Conference When: Tuesday, November 19th, 2024 What: Barclays 22nd Annual Global Technology Conference When: Wednesday, December 11 th, 2024 What: Nasdaq 51st Investor Conference When: Wednesday, December 11 th, 2024 To view the webcast and replay for conferences please use the link below.
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
The annual run rate of recurring revenue continues to grow at a double-digit rate. Free cash flow is growing more than recurring revenue growth.
NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
– Continued strong revenue performance – – NDAs for sepiapterin and Translarna™ submitted to FDA – – Positive interim data readout from PTC518 PIVOT-HD study – – On track to achieve remaining 2024 clinical and regulatory milestones – WARREN, N.J. , Aug. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2024.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.